title: Upregulation of long noncoding RNA zinc finger antisense 1 enhances epithelial-mesenchymal transition in vitro and predicts poor prognosis in glioma.
abstract: Increasing evidence indicates that long noncoding RNAs play important roles in development and progression of various cancers. Zinc finger antisense 1 is a novel long noncoding RNA whose clinical significance, biological function, and underlying mechanism are still undetermined in glioma. In this study, we reported that zinc finger antisense 1 expression was markedly upregulated in glioma and tightly correlated with clinical stage. Moreover, patients with high zinc finger antisense 1 expression had shorter survival. Multivariate Cox regression analysis provided a clue that, probably, zinc finger antisense 1 level could serve as an independent prognostic factor for glioma. Functionally, zinc finger antisense 1 acted as an oncogene in glioma because its knockdown could promote apoptosis and significantly inhibit cell proliferation, migration, and invasion. Furthermore, zinc finger antisense 1 silencing could result in cell cycle arrest at the G0/G1 phase and correspondingly decrease the percentage of S phase cells in both U87 and U251 cell lines. Moreover, it was found that silenced zinc finger antisense 1 could impair migration and invasion by inhibiting the epithelial-mesenchymal transition through reducing the expression of MMP2, MMP9, N-cadherin, Integrin β1, ZEB1, Twist, and Snail as well as increasing E-cadherin level in glioma. Taken together, our data identified that zinc finger antisense 1 might act as a valuable prognostic biomarker and potential therapeutic target for glioma.
authors.affiliation: 1 Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, P.R. China.|2 Hunan Key Laboratory of Pharmacogenetics, Institute of Clinical Pharmacology, Central South University, Changsha, P.R. China.
authors.forename: Qiao-Li
authors.initials: QL
authors.lastname: Lv
authors.affiliation: 3 Department of Oncology, Changsha Central Hospital, Changsha, P.R. China.
authors.forename: Shu-Hui
authors.initials: SH
authors.lastname: Chen
authors.affiliation: 1 Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, P.R. China.|2 Hunan Key Laboratory of Pharmacogenetics, Institute of Clinical Pharmacology, Central South University, Changsha, P.R. China.
authors.forename: Xue
authors.initials: X
authors.lastname: Zhang
authors.affiliation: 1 Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, P.R. China.|2 Hunan Key Laboratory of Pharmacogenetics, Institute of Clinical Pharmacology, Central South University, Changsha, P.R. China.
authors.forename: Bao
authors.initials: B
authors.lastname: Sun
authors.affiliation: 1 Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, P.R. China.|2 Hunan Key Laboratory of Pharmacogenetics, Institute of Clinical Pharmacology, Central South University, Changsha, P.R. China.
authors.forename: Lei
authors.initials: L
authors.lastname: Hu
authors.affiliation: 4 Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, P.R. China.
authors.forename: Qiang
authors.initials: Q
authors.lastname: Qu
authors.affiliation: 5 Department of Neurology, The Brain Hospital of Hunan Province, Changsha, P.R. China.
authors.forename: Yuan-Tao
authors.initials: YT
authors.lastname: Huang
authors.affiliation: 3 Department of Oncology, Changsha Central Hospital, Changsha, P.R. China.
authors.forename: Gui-Hua
authors.initials: GH
authors.lastname: Wang
authors.affiliation: 1 Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, P.R. China.|2 Hunan Key Laboratory of Pharmacogenetics, Institute of Clinical Pharmacology, Central South University, Changsha, P.R. China.
authors.forename: Yan-Ling
authors.initials: YL
authors.lastname: Liu
authors.affiliation: 6 Department of Oncology, Xiangya Hospital, Central South University, Changsha, P.R. China.
authors.forename: Ying-Ying
authors.initials: YY
authors.lastname: Zhang
authors.affiliation: 1 Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, P.R. China.|2 Hunan Key Laboratory of Pharmacogenetics, Institute of Clinical Pharmacology, Central South University, Changsha, P.R. China.
authors.forename: Hong-Hao
authors.initials: HH
authors.lastname: Zhou
mesh_terms: D000328:Adult; D000368:Aged; D017209:Apoptosis / Q000235:genetics; D059447:Cell Cycle Checkpoints / Q000235:genetics; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000235:genetics; D049109:Cell Proliferation / Q000235:genetics*; D058750:Epithelial-Mesenchymal Transition / Q000235:genetics; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D005910:Glioma / Q000235:genetics* / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness / Q000235:genetics; D009363:Neoplasm Proteins / Q000096:biosynthesis; D011379:Prognosis; D062085:RNA, Long Noncoding / Q000235:genetics*
chemical_list: D009363:Neoplasm Proteins; D062085:RNA, Long Noncoding; C000611949:ZFAS1 long non-coding RNA, human
keywords: Long noncoding RNA; cell cycle; epithelial–mesenchymal transition; glioma; long noncoding RNA zinc finger antisense 1